Kun-Ming Chan1, Tsung-Han Wu2, Chih-Hsien Cheng2, Chen-Fang Lee2, Ting-Jung Wu2, Hong-Shiue Chou2, Wei-Chen Lee2. 1. Department of General Surgery & Department of Organs Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, 5 Fu-Hsing Street, Kwei-Shan District, Taoyuan City, 33305, Taiwan. chankunming@adm.cgmh.org.tw. 2. Department of General Surgery & Department of Organs Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, 5 Fu-Hsing Street, Kwei-Shan District, Taoyuan City, 33305, Taiwan.
Abstract
BACKGROUND: Chronic viral hepatitis remains a major etiology of liver cirrhosis and hepatocellular carcinoma. Liver transplantation has been considered an effective treatment for this condition. This study aims to analyze living donor liver transplantation for patients with hepatocellular carcinoma and its relationship with hepatitis virus status. METHODS: A retrospective analysis of 268 patients who received living donor liver transplantation for hepatocellular carcinoma was performed. Patients were analyzed according to their serologic status of hepatitis virus; clinicopathologic features, operative parameters, and outcomes were also assessed and compared. RESULTS: Twenty-three patients (8.6%) had hepatocellular carcinoma recurrence following liver transplantation; the most common pattern of recurrence was systemic spreading (n = 10). Hepatitis B virus relapse was encountered in 41 out of 188 patients (21.8%) with hepatitis B virus-positive, and hepatitis C virus reactivation was noted in 48 (60.8%) patients among 79 hepatitis C virus-positive patients. Incidence of hepatitis C virus reactivation was significantly higher than that of hepatitis B virus relapse (p < 0.0001). Hepatocellular carcinoma recurrence and overall survival were not significantly different in relation to hepatitis virus; however, patients who had hepatocellular carcinoma recurrence combined with hepatitis virus reinfection had the significantly lowest survival rate compared with other groups (p < 0.0001). CONCLUSION: Living donor liver transplantation based on expanded hepatocellular carcinoma criteria achieved a satisfactory result, but reinfection of hepatic virus remains a great concern particularly in patient with hepatitis C. Moreover, hepatocellular carcinoma recurrence accompanied with reinfection of hepatic virus after liver transplantation is associated with inferior outcomes.
BACKGROUND:Chronic viral hepatitis remains a major etiology of liver cirrhosis and hepatocellular carcinoma. Liver transplantation has been considered an effective treatment for this condition. This study aims to analyze living donor liver transplantation for patients with hepatocellular carcinoma and its relationship with hepatitis virus status. METHODS: A retrospective analysis of 268 patients who received living donor liver transplantation for hepatocellular carcinoma was performed. Patients were analyzed according to their serologic status of hepatitis virus; clinicopathologic features, operative parameters, and outcomes were also assessed and compared. RESULTS: Twenty-three patients (8.6%) had hepatocellular carcinoma recurrence following liver transplantation; the most common pattern of recurrence was systemic spreading (n = 10). Hepatitis B virus relapse was encountered in 41 out of 188 patients (21.8%) with hepatitis B virus-positive, and hepatitis C virus reactivation was noted in 48 (60.8%) patients among 79 hepatitis C virus-positive patients. Incidence of hepatitis C virus reactivation was significantly higher than that of hepatitis B virus relapse (p < 0.0001). Hepatocellular carcinoma recurrence and overall survival were not significantly different in relation to hepatitis virus; however, patients who had hepatocellular carcinoma recurrence combined with hepatitis virus reinfection had the significantly lowest survival rate compared with other groups (p < 0.0001). CONCLUSION: Living donor liver transplantation based on expanded hepatocellular carcinoma criteria achieved a satisfactory result, but reinfection of hepatic virus remains a great concern particularly in patient with hepatitis C. Moreover, hepatocellular carcinoma recurrence accompanied with reinfection of hepatic virus after liver transplantation is associated with inferior outcomes.
Authors: Luca S Belli; Andrew K Burroughs; Patrizia Burra; Alberto B Alberti; Dimitrios Samonakis; Calogero Cammà; Luciano De Carlis; Ernesto Minola; Alberto Quaglia; Claudio Zavaglia; Marcello Vangeli; David Patch; Amar Dhillon; Umberto Cillo; Maria Guido; Stefano Fagiuoli; Alessandro Giacomoni; Omar A Slim; Aldo Airoldi; Sara Boninsegna; Brian R Davidson; Keith Rolles; Giovambattista Pinzello Journal: Liver Transpl Date: 2007-05 Impact factor: 5.799
Authors: Edward J Gane; Peter W Angus; Simone Strasser; Darrell H G Crawford; John Ring; Gary P Jeffrey; Geoffrey W McCaughan Journal: Gastroenterology Date: 2007-01-05 Impact factor: 22.682
Authors: Luciana C Faria; Michelle Gigou; Anne M Roque-Afonso; Mylene Sebagh; Bruno Roche; Guillaume Fallot; Teresa C A Ferrari; Catherine Guettier; Elisabeth Dussaix; Denis Castaing; Christian Brechot; Didier Samuel Journal: Gastroenterology Date: 2008-03-04 Impact factor: 22.682
Authors: Mashaal Dhir; Alyson A Melin; Jeffrey Douaiher; Chi Lin; Weining Ken Zhen; Shahid M Hussain; Jean-Francois H Geschwind; Maria B Majella Doyle; Ghassan K Abou-Alfa; Chandrakanth Are Journal: Ann Surg Date: 2016-06 Impact factor: 12.969